The “Journal of Medicinal Chemistry” publishes a paper on the identification of new and highly selective inhibitors of histone deacetylase 6 (HDAC6) by the Italfarmaco drug discovery team. HDAC6 is emerging as an important target for the development of antineoplastic, respiratory and neuroprotective drugs. The pubblication “Novel Benzohydroxamate-based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis and Biological Evaluation” by: Vergani, Barbara; Sandrone, Giovanni; Marchini, Mattia; Ripamonti, Chiara; Cellupica, Edoardo; Galbiati, Elisabetta; Caprini, Gianluca; Pavich, Gianfranco; Porro, Giulia; Rocchio, Ilaria; Lattanzio, Maria; Pezzuto, Marcello; Skorupska, Malgorzata; Cordella, Paola; Pagani, Paolo; Pozzi, Pietro; Pomarico, Roberta; Modena, Daniela; Leoni, Flavio; Perego, Raffaella; Fossati, Gianluca; Steinkühler, Christian; Stevenazzi, Andrea describes novel drug candidates with best in class properties and highlights the expertise of the Italfarmaco group in the development of highly innovative epigenetic drugs.
https://www.ncbi.nlm.nih.gov/pubmed/31710483